Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 340 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Celecoxib Clear all
Terminated Phase 2 Interventional

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

NCT00037180
View directory record Official record
Conditions
Neoplasm Metastasis, Colorectal Neoplasms
Interventions
Celecoxib, Irinotecan, 5-fluorouracil, Leucovorin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
12
States / cities
Mobile, Alabama • Fort Lauderdale, Florida • Port Saint Lucie, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2008 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers

NCT01021215
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Zileuton, Celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Sep 2, 2026, 6:54 AM EDT
Terminated Phase 4 Interventional

Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

NCT00904397
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Lidoderm®, Celecoxib
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
21
States / cities
Northport, Alabama • Phoenix, Arizona • Beverly Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 2, 2026, 6:54 AM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 6:54 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

NCT03686657
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
Drug
Lead sponsor
ARKAY Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

NCT02151448
View directory record Official record
Conditions
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions
DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
Biological · Drug
Lead sponsor
David Bartlett
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 2, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT05343013
View directory record Official record
Conditions
Colorectal Cancer
Interventions
TAS-102
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 2, 2026, 6:54 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

NCT00027976
View directory record Official record
Conditions
Precancerous Condition
Interventions
celecoxib, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
7
States / cities
Birmingham, Alabama • Irvine, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Toradol v. Celecoxib for Postoperative Pain

NCT03331315
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Celecoxib, Ketorolac
Drug
Lead sponsor
Michael Ulm, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 2Phase 3 Interventional

Enhanced Recovery After Surgery in Orthopaedic Spine Surgery

NCT04562610
View directory record Official record
Conditions
Lumbar Surgery
Interventions
Intravenous Infusion group, All oral administration group
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 105 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 2, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer

NCT00527982
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
Celecoxib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 2, 2026, 6:54 AM EDT
Withdrawn Phase 2 Interventional

Celecoxib in Preventing Skin Cancer

NCT00025051
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy

NCT04429022
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, Acetaminophen, Celecoxib, Ketorolac, Paracervical block with ropivacaine, Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites, Hydromorphone, Oxycodone
Drug · Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
25 Years to 90 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 2, 2026, 6:54 AM EDT
Recruiting Phase 4 Interventional

Single Shot Exparel vs Catheters in Lower Extremity Trauma

NCT07221019
View directory record Official record
Conditions
Fracture Dislocation of Ankle Joint, Fracture Leg, Fracture Femur, Fracture Lower Leg, Fracture
Interventions
Bupivacaine, Exparel + Bupivacaine
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

NCT00154219
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Lumiracoxib (drug)
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00538031
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
cyclophosphamide, celecoxib
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 2, 2026, 6:54 AM EDT
Terminated Phase 1 Interventional

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

NCT01143545
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma, Thymic Carcinoma
Interventions
Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 2, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

NCT00256321
View directory record Official record
Conditions
Gastric Carcinoma, Gastroesophageal Junction Carcinoma
Interventions
Oxaliplatin, Capecitabine, Celecoxib
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 2Phase 3 Interventional

Celecoxib in Treating Patients With Bladder Cancer

NCT00006124
View directory record Official record
Conditions
Recurrent Bladder Cancer
Interventions
celecoxib, placebo
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

NCT01901679
View directory record Official record
Conditions
Obesity
Interventions
Celebrex
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure

NCT00624559
View directory record Official record
Conditions
Hypertension
Interventions
celecoxib (Celebrex), Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
22 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer

NCT00230399
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, Capecitabine, Irinotecan
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Sep 2, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery

NCT04015908
View directory record Official record
Conditions
Opioid Use
Interventions
Celecoxib, Acetaminophen, Pregabalin, Oxycodone, Percocet
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 2, 2026, 6:54 AM EDT